Allergy Therapeutics PLC Presentation at Jefferies Healthcare Conference
12 November 2018 - 11:00PM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
12 November 2018
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Allergy Therapeutics to present at Jefferies 2018 London
Healthcare Conference
12 November 2018 Allergy Therapeutics (AIM:AGY), the fully
integrated specialty pharmaceutical company specialising in allergy
vaccines, announces that Manuel Llobet, CEO, and Nick Wykeman, CFO,
will attend the Jefferies Healthcare Conference in London on
Wednesday 14 November 2018.
Nick Wykeman, CFO, will lead an investor presentation at 15.20
GMT on Wednesday 14 November.
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Emma Earl, Corporate Finance
Erik Anderson, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Nicholas Brown / Olivia
Manser
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology group focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and
third-party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional fourteen
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved 10% compound annual
growth since formation, employs c.500 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAKMMMMMZRGRZM
(END) Dow Jones Newswires
November 12, 2018 07:00 ET (12:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024